Scopus BioPharma Inc. (SCPS) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerScopus BioPharma Inc. (SCPS) trades at $0.0004. Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology gene therapies and other therapeutics targeting serious diseases. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for SCPS: SCPS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Scopus BioPharma Inc. (SCPS) Healthcare & Pipeline Overview
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company developing immuno-oncology gene therapies and other therapeutics for serious diseases, leveraging its Duet Platform and MRI-1867, while forging strategic partnerships to advance its pipeline in the competitive biotechnology sector.
What Is the Investment Thesis for SCPS?
Scopus BioPharma Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on immuno-oncology gene therapy, particularly its Duet Platform and MRI-1867, offers potential for significant breakthroughs in cancer treatment. However, as a clinical-stage company with a market capitalization of $0.00 billion, Scopus BioPharma faces substantial challenges in navigating the regulatory approval process and securing funding for ongoing research and development. Key value drivers include the successful progression of its lead programs through clinical trials and the establishment of additional strategic partnerships. Upcoming catalysts include the release of clinical trial data and potential FDA approvals. Potential risks include clinical trial failures, regulatory setbacks, and the need for additional capital raising, which could dilute existing shareholders.
Based on FMP financials and quantitative analysis
SCPS Key Highlights
Scopus BioPharma Inc. is a clinical-stage biopharmaceutical company focused on developing transformational therapeutics targeting serious diseases.
- The company's lead development programs are in immuno-oncology gene therapy for the treatment of various cancers.
- Scopus BioPharma offers the Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors.
- MRI-1867 is a rationally designed, orally available, dual-action, hybrid, and small molecule.
- The company has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem.
Who Are SCPS's Competitors?
SCPS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| ICCC ImmuCell Corporation | $9.75 | +1.56% | $88.2M | 77 5-pillar |
| RLYB Rallybio Corporation | $17.08 | +1.91% | $90.6M | 83 5-pillar |
| ALPX Alopexx, Inc. | $9.96 | 0.00% | $119M | 65 5-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.49 | +0.22% | $184M | 76 5-pillar |
| ANTX AN2 Therapeutics, Inc. | $5.71 | +1.60% | $206M | 67 5-pillar |
| PLX Protalix BioTherapeutics, Inc. | $2.71 | +1.12% | $218M | 73 5-pillar |
| NAGE Niagen Bioscience Inc | $2.79 | +4.10% | $222M | 68 5-pillar |
| QTTB Q32 Bio Inc. | $8.23 | -0.24% | $245M | 67 5-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SCPS's Key Strengths?
Innovative technology platforms (Duet Platform, MRI-1867).
- Strategic partnerships with leading research institutions.
- Focus on high-growth immuno-oncology market.
- Experienced management team.
What Are SCPS's Weaknesses?
Clinical-stage company with no approved products.
- Limited financial resources.
- High dependence on strategic partnerships.
- OTC market listing.
What Are the Key Risks for SCPS?
Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for its therapeutic candidates.
- Regulatory setbacks and delays in obtaining approvals.
- Competition from established pharmaceutical companies and other biotech firms.
- Need for additional capital raising, which could dilute existing shareholders.
- Intellectual property disputes and patent challenges.
What Are SCPS's Competitive Advantages?
- Proprietary technology platforms (Duet Platform, MRI-1867).
- Strategic partnerships with leading research institutions.
- Intellectual property protection (patents and trademarks).
What Does SCPS Do?
Scopus BioPharma Inc., established in 2017 and headquartered in New York City, is a clinical-stage biopharmaceutical company dedicated to creating transformational therapeutics for serious diseases, particularly in the realm of immuno-oncology. The company's lead development programs are centered around immuno-oncology gene therapy for the treatment of various cancers. Scopus BioPharma's portfolio includes the Duet Platform, which features CpG signal transducer and activator of transcription 3 (STAT3) inhibitors, and MRI-1867, a rationally designed, orally available, dual-action, hybrid, and small molecule that acts as an inverse agonist of the endocannabinoid system/cannabinoid receptor 1 and an inhibitor of inducible nitric oxide synthase. These innovative approaches reflect Scopus BioPharma's commitment to addressing unmet medical needs through cutting-edge research and development. The company has established strategic partnerships with renowned institutions such as the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem to bolster its research and development efforts and accelerate the advancement of its therapeutic programs. Formerly known as Project18 Inc., Scopus BioPharma Inc. is focused on translating scientific discoveries into effective therapies that can improve patient outcomes.
What Products and Services Does SCPS Offer?
- Develop immuno-oncology gene therapies for cancer treatment.
- Offer the Duet Platform, featuring CpG signal transducer and activator of transcription 3 (STAT3) inhibitors.
- Develop MRI-1867, a dual-action molecule targeting the endocannabinoid system and inducible nitric oxide synthase.
- Engage in strategic partnerships with research institutions.
- Conduct clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
- Seek regulatory approvals for its therapies from agencies like the FDA.
- Focus on transformational therapeutics for serious diseases.
How Does SCPS Make Money?
- Develop and patent novel therapeutic candidates.
- Out-license or co-develop its therapeutic candidates with larger pharmaceutical companies.
- Generate revenue through milestone payments and royalties from partnered programs.
What Industry Does SCPS Operate In?
Scopus BioPharma Inc. operates within the highly competitive biotechnology industry, which is characterized by rapid innovation, intense research and development, and stringent regulatory requirements. Scopus BioPharma's focus on immuno-oncology gene therapy positions it within a high-growth segment of the market, but it faces competition from established pharmaceutical companies and other emerging biotech firms. The company's success will depend on its ability to differentiate its therapeutic programs, secure regulatory approvals, and establish strategic partnerships to expand its market reach.
Who Are SCPS's Key Customers?
- Pharmaceutical companies seeking to expand their oncology portfolios.
- Patients suffering from cancers and other serious diseases.
- Research institutions and hospitals.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Earnings Track Record
Scopus BioPharma Inc. has beaten Wall Street's EPS estimate in 2 of its last 4 reported quarters — more hits than misses. Reported results have landed about 99.5% below estimates on average.
Financial Health
Scopus BioPharma Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Scopus BioPharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Alan D. Horsager. SCPS has traded publicly since 2020.
Insider Activity
12 transactions · 8 purchases, 0 sales, 4 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
SCPS Financials
SCPS Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Dec 19, 2022
SCPS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SCPS.
Price Targets
Wall Street price target analysis for SCPS.
SCPS MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SCPS; grades run from A+ (80-100) to F (below 30).
Leadership: Alan D. Horsager
CEO
Alan D. Horsager serves as the CEO of Scopus BioPharma Inc., managing a team of 13 employees. His background includes extensive experience in the pharmaceutical and biotechnology industries, with a focus on strategic leadership and business development. He has held various executive positions at both public and private companies, contributing to the advancement of innovative therapies. Horsager's expertise spans areas such as drug development, clinical trials, and commercialization strategies.
Track Record: Under Alan D. Horsager's leadership, Scopus BioPharma Inc. has focused on advancing its lead development programs in immuno-oncology gene therapy and establishing strategic partnerships with renowned research institutions. Key milestones include the development of the Duet Platform and MRI-1867, as well as collaborations with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. Horsager's strategic decisions have been instrumental in shaping the company's direction and driving its growth.
SCPS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Scopus BioPharma Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to greater price volatility. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same rigorous listing standards, potentially increasing investment risk. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Limited liquidity and trading volume.
- Lack of regulatory oversight and financial transparency.
- Potential for price manipulation and fraud.
- Higher risk of delisting or bankruptcy.
- Difficulty in obtaining accurate and reliable information.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Determine the company's capital structure and funding needs.
- Understand the risks associated with investing in OTC stocks.
- Consult with a qualified financial advisor.
- Strategic partnerships with reputable research institutions.
- Focus on innovative therapeutic programs.
- Experienced management team with industry expertise.
- Intellectual property protection (patents and trademarks).
- Active engagement with investors and stakeholders.
Scopus BioPharma Inc. Healthcare Stock: Key Questions Answered
What do analysts say about SCPS stock?
As of 2026-03-16, there is no readily available analyst consensus on Scopus BioPharma Inc. (SCPS) due to its OTC listing and limited market capitalization. Key valuation metrics are not applicable given the company's current financial performance.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.